ESMO 2025 key updates in different cancer types provided by @Dr. Mohamed Emam
Lung update:
HARMONi-6
In untreated advanced squamous NSCLC, ivonescimab plus chemotherapy significantly improved progression-free survival over tislelizumab plus chemotherapy, with consistent benefit across PD-L1 levels and manageable safety
OptiTROP-Lung04
In EGFR-mutated advanced NSCLC that progressed after EGFR-TKI therapy, sacituzumab tirumotecan significantly improved progression-free and overall survival compared with platinum-based chemotherapy, with manageable toxicity.
DREAM3R(LBA104)
Durvalumab combined with pemetrexed and platinum chemotherapy increased response rates but showed similar survival to chemotherapy alone in advanced pleural mesothelioma, with consistent safety and no predictive role for PD-L1.
NORTHSTAR
In patients with EGFR mutant NSCLC, consolidation local radiotherapy added to osimertinib improved PFS
Breast update:
DESTINY-Breast05
In patients with high risk breast cancer HER2 positive with residual disease after neoadjuvant therapy, T-DXd demonstrated superior efficacy with manageable safety, compared to TDM-1.
Destiny breast 09 (LBA18)
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic breast cancer, with a consistent safety profile.
DESTINY-Breast11
trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel plus trastuzumab and pertuzumab (T-DXd-THP) versus dose-dense doxorubicin plus cyclophosphamide followed by THP (ddAC-THP) as neoadjuvant therapy for high-risk HER2-positive early breast cancer
ASCENT-03
In patients with advanced triple-negative breast cancer ineligible for PD-1 or PD-L1 inhibitors, sacituzumab govitecan significantly improved progression-free survival and response durability compared to standard chemotherapy, with a similar safety profile.
GI update:
FOxTROT and NICHE-2 Comparison(724O)
Neoadjuvant nivolumab/ipilimumab achieved superior 3-year disease-free survival and pathological response compared to chemotherapy in locally advanced dMMR colon cancer, supporting its use as the preferred neoadjuvant approach.
CARES-009(1470O)
Perioperative camrelizumab plus rivoceranib significantly improved event-free survival and pathological response compared to surgery alone in resectable hepatocellular carcinoma at intermediate or high risk of recurrence.
GU Update:
SGNDV-001
Disitamab vedotin combined with toripalimab significantly improves survival and response rates with a more favorable safety profile compared to chemotherapy in untreated HER2-expressing advanced urothelial cancer.
KEYNOTE-905/EV-303
In patients with muscle invasive bladder cancer ineligible to cisplatin , perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus surgery alone significantly improved event-free survival overall survival pathological complete response rate
PSMAddition(LBA6)
In PSMA-positive metastatic hormone-sensitive prostate cancer, adding [¹⁷⁷Lu]Lu-PSMA-617 to ADT plus ARPI significantly improved radiographic progression-free survival with manageable toxicity and no meaningful impact on quality of life.
CAPItello-281 Phase III study
In PTEN-deficient metastatic hormone-sensitive prostate cancer, adding the AKT inhibitor capivasertib to abiraterone and ADT significantly prolonged radiographic progression-free survival with manageable, expected toxicities.
EnzaRad(LBA86)
Adding enzalutamide to ADT and radiation provided limited overall survival benefit in high-risk localized or locally advanced prostate cancer, with greater metastasis-free survival seen in patients with positive pelvic nodes or planned pelvic radiation.
EMBARK(LBA87)
Enzalutamide plus leuprolide significantly improves overall survival and delays disease progression compared with leuprolide alone in high-risk biochemically recurrent prostate cancer, supporting it as a standard-of-care option.
